Risk Models to Predict Hypertension: A Systematic Review

Background As well as being a risk factor for cardiovascular disease, hypertension is also a health condition in its own right. Risk prediction models may be of value in identifying those individuals at risk of developing hypertension who are likely to benefit most from interventions. Methods and Findings To synthesize existing evidence on the performance of these models, we searched MEDLINE and EMBASE; examined bibliographies of retrieved articles; contacted experts in the field; and searched our own files. Dual review of identified studies was conducted. Included studies had to report on the development, validation, or impact analysis of a hypertension risk prediction model. For each publication, information was extracted on study design and characteristics, predictors, model discrimination, calibration and reclassification ability, validation and impact analysis. Eleven studies reporting on 15 different hypertension prediction risk models were identified. Age, sex, body mass index, diabetes status, and blood pressure variables were the most common predictor variables included in models. Most risk models had acceptable-to-good discriminatory ability (C-statistic>0.70) in the derivation sample. Calibration was less commonly assessed, but overall acceptable. Two hypertension risk models, the Framingham and Hopkins, have been externally validated, displaying acceptable-to-good discrimination, and C-statistic ranging from 0.71 to 0.81. Lack of individual-level data precluded analyses of the risk models in subgroups. Conclusions The discrimination ability of existing hypertension risk prediction tools is acceptable, but the impact of using these tools on prescriptions and outcomes of hypertension prevention is unclear.

[1]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[2]  Douglas G Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[3]  A. Kraja,et al.  Genetics of Hypertension and Cardiovascular Disease and Their Interconnected Pathways: Lessons from Large Studies , 2011, Current hypertension reports.

[4]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[5]  A. Evans,et al.  Translating Clinical Research into Clinical Practice: Impact of Using Prediction Rules To Make Decisions , 2006, Annals of Internal Medicine.

[6]  K. Chien,et al.  Prediction models for the risk of new-onset hypertension in ethnic Chinese in Taiwan , 2011, Journal of Human Hypertension.

[7]  N. Tangri,et al.  A predictive model for progression of chronic kidney disease to kidney failure. , 2011, JAMA.

[8]  R. Vasan,et al.  The progression from hypertension to congestive heart failure. , 1996, JAMA.

[9]  Daniel Levy,et al.  Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study , 2001, The Lancet.

[10]  Devin M Mann,et al.  Comparison of the Framingham Heart Study Hypertension Model With Blood Pressure Alone in the Prediction of Risk of Hypertension: The Multi-Ethnic Study of Atherosclerosis , 2010, Hypertension.

[11]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[12]  K G M Moons,et al.  Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review , 2011, Heart.

[13]  Olle Melander,et al.  Prediction of Blood Pressure Changes Over Time and Incidence of Hypertension by a Genetic Risk Score in Swedes , 2013, Hypertension.

[14]  M. Woodward,et al.  Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker , 2012, Heart.

[15]  D. Levy,et al.  A Risk Score for Predicting Near-Term Incidence of Hypertension: The Framingham Heart Study , 2008, Annals of Internal Medicine.

[16]  M. Cho,et al.  Predicting the Risk of Incident Hypertension in a Korean Middle‐Aged Population: Korean Genome and Epidemiology Study , 2013, Journal of clinical hypertension.

[17]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[18]  M. Woodward,et al.  Risk prediction models: II. External validation, model updating, and impact assessment , 2012, Heart.

[19]  Oscar H Franco,et al.  Blood Pressure in Adulthood and Life Expectancy With Cardiovascular Disease in Men and Women: Life Course Analysis , 2005, Hypertension.

[20]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[21]  Sudha Seshadri,et al.  Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. , 2002, JAMA.

[22]  G. Mensah,et al.  Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000. , 2005, Archives of internal medicine.

[23]  Nader Rifai,et al.  Multiple Biomarkers and the Risk of Incident Hypertension , 2007, Hypertension.

[24]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[25]  Nancy R Cook,et al.  Prediction of incident hypertension risk in women with currently normal blood pressure. , 2009, The American journal of medicine.

[26]  K. Anderson,et al.  Cardiovascular disease risk profiles. , 1991, American heart journal.

[27]  D. Levy,et al.  Relations of Matrix Remodeling Biomarkers to Blood Pressure Progression and Incidence of Hypertension in the Community , 2009, Circulation.

[28]  S. Oparil,et al.  Feasibility of treating prehypertension with an angiotensin-receptor blocker. , 2006, The New England journal of medicine.

[29]  A. Rodgers,et al.  Global burden of blood-pressure-related disease, 2001 , 2008, The Lancet.

[30]  G David Batty,et al.  Incremental Predictive Value of Adding Past Blood Pressure Measurements to the Framingham Hypertension Risk Equation: The Whitehall II Study , 2010, Hypertension.

[31]  A. LaCroix,et al.  The prediction of midlife coronary heart disease and hypertension in young adults: the Johns Hopkins multiple risk equations. , 1990, American journal of preventive medicine.

[32]  Farzad Hadaegh,et al.  A point-score system superior to blood pressure measures alone for predicting incident hypertension: Tehran Lipid and Glucose Study , 2011, Journal of hypertension.

[33]  M. Jokela,et al.  Validating the Framingham Hypertension Risk Score: Results From the Whitehall II Study , 2009, Hypertension.

[34]  Anthony J Viera,et al.  A Hypertension Risk Score for Middle‐Aged and Older Adults , 2010, Journal of clinical hypertension.

[35]  Youfa Wang,et al.  The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. , 2004, Archives of internal medicine.

[36]  B. Norrving,et al.  Global atlas on cardiovascular disease prevention and control. , 2011 .

[37]  P. Whelton,et al.  Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. , 2000, Hypertension.